Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of diaziquone.

S Frytak, R T Eagan, M M Ames

    Cancer Treatment Reports
    |July 1, 1984
    PubMed
    Summary

    This phase I study of diaziquone (AZQ) found myelosuppression to be dose-limiting and unpredictable. Recommended dosing involves single IV injections of 22.5-27.5 mg/m2 every 4-5 weeks.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

    Clinical pharmacology and therapeutics·2013
    Same author

    Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

    Bone marrow transplantation·2009
    Same author

    Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

    Clinical pharmacology and therapeutics·2007
    Same author

    Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

    Clinical pharmacology and therapeutics·2007
    Same author

    The Hsp90 chaperone complex as a novel target for cancer therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2003
    Same author

    Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.

    Leukemia & lymphoma·2002

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Diaziquone (AZQ) is an investigational anticancer agent.
    • Phase I studies are crucial for determining safe and effective dosing regimens for new cancer therapies.

    Purpose of the Study:

    • To evaluate the safety and tolerability of diaziquone (AZQ) in cancer patients.
    • To identify dose-limiting toxicities and establish a recommended phase II dose and schedule.
    • To explore the pharmacokinetics of AZQ.

    Main Methods:

    • A phase I clinical trial involving 28 patients with various cancers, primarily gastrointestinal neoplasms.
    • Administration of single intravenous doses of diaziquone (AZQ) ranging from 2 to 27.5 mg/m2.
    • Monitoring for adverse events, particularly hematologic toxicity, and pharmacokinetic profiling.

    Main Results:

    • Myelosuppression was identified as the dose-limiting toxicity, exhibiting cumulative and unpredictable patterns.
    • No consistent correlation was found between pretreatment patient characteristics and hematologic toxicity.
    • No objective tumor responses were observed in this patient cohort.
    • Pharmacokinetic analysis indicated that AZQ plasma elimination is best described by a two-compartment open model.

    Conclusions:

    • A suitable initial dosing schedule for diaziquone (AZQ) is a single intravenous injection of 22.5-27.5 mg/m2 every 4-5 weeks.
    • Further investigation is needed to understand and potentially mitigate the unpredictable myelosuppression associated with AZQ.
    • The pharmacokinetic profile suggests rapid elimination of the parent drug.

    Related Experiment Videos